Lukas Kazianka
A5070870023- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Galectins and Cancer Biology
- Neuroendocrine Tumor Research Advances
- Single-cell and spatial transcriptomics
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Cell Image Analysis Techniques
- Growth Hormone and Insulin-like Growth Factors
- Genomics and Chromatin Dynamics
- Economic and Financial Impacts of Cancer
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Acute Lymphoblastic Leukemia research
- Bariatric Surgery and Outcomes
- Immune Response and Inflammation
- Intestinal Malrotation and Obstruction Disorders
- Viral Infectious Diseases and Gene Expression in Insects
Medical University of Vienna
2015-2024
Abstract Personalized medicine aims to match the right drug with patient by using specific features of individual patient's tumor. However, current strategies personalized therapy matching provide treatment opportunities for less than 10% patients cancer. A promising method may be profiling biopsy specimens single-cell resolution directly quantify effects. We prospectively tested an image-based functional precision (scFPM) approach guide treatments in 143 advanced aggressive hematologic...
Patients with refractory or relapsed haematological malignancies have few treatment options and short survival times. Identification of effective therapies genomic-based precision medicine is hampered by intratumour heterogeneity incomplete understanding the contribution various mutations within specific cancer phenotypes. Ex-vivo drug-response profiling in patient biopsies might aid identification; however, proof its clinical utility limited.We investigated feasibility impact...
For PET imaging of mantle cell lymphoma (MCL), [18F]FDG (2-deoxy-2-[18F]fluoro-D-glucose) is the currently recommended radiotracer, although uptake variable and bone marrow evaluation limited. In this prospective study, we evaluated novel CXCR4 (G-protein-coupled C-X-C chemokine receptor type 4) tracer [68Ga]Pentixafor in MCL patients, compared it to [18F]FDG. Methods: patients underwent [68Ga]Pentixafor-PET/MRI, and, if required for routine purposes, also [18F]FDG-PET/MRI, before treatment....
Bleeding because of impaired platelet function is a major side effect the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced aggregation (RIPA) in 64 patients with chronic lymphocytic leukemia (CLL) under ibrutinib at 287 time points. Eighty-seven bleeding episodes 39 were registered (85 Common Toxicity Criteria (CTC) grade 1 or 2, 2 CTC 3) during median observation period 10.9 months. At times bleeding, RIPA values significantly lower (14 vs 28...
Abstract Bruton tyrosine kinase inhibitor ibrutinib is effective in treating chronic lymphocytic leukemia (CLL). However, after treatment initiation, patients frequently experience an increase of CLL blood cell count. This phenomenon clinical practice thought to reflect a “compartment shift” cells from lymph nodes the peripheral blood, but actual shifting has not yet been demonstrated. Using [68Ga]Pentixafor-PET/MRI for vivo CXCR4 visualization, we here provide images topical changes upon...
[S-methyl-11C]-L-methionine ([11C]MET) uptake in the pancreas might be a central indicator of beta cell function. Since gastric emptying was recently shown to influence glycemic control subjects after pancreaticoduodenectomy (PD, surgical treatment neoplasms head), we looked for imaginable relationships between emptying, pre- and postprandial insulin concentrations, [11C]MET uptake.Nineteen tumor-free survivors PD (age mean ± SD: 61 8.7 yrs.; 10 male, 9 female) healthy controls (age: 27 7 3...
Summary paragraph The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of the hematopoietic master regulator PU.1 1–4 . gene regulated through enhancer-promoter interactions within topologically associated domain (TAD) 5,6 levels increase during myeloid while failure to do so results in leukemia 7 In contrast, T-cell requires be completely switched off 8–10 Little known about mechanisms repression, physiological...
Background: As previously shown, pancreaticoduodenectomy (PD) results in accelerated gastric emptying and enhanced release of the incretin hormone GLP-1 which also constrains exocrine pancreas for uptake 11C-methionine is an established marker. To assess possible effects PD on function pancreatic remnant postprandial was measured by PET-CT patients who have undergone healthy controls.
<div>Abstract<p>Bruton tyrosine kinase inhibitor ibrutinib is effective in treating chronic lymphocytic leukemia (CLL). However, after treatment initiation, patients frequently experience an increase of CLL blood cell count. This phenomenon clinical practice thought to reflect a “compartment shift” cells from lymph nodes the peripheral blood, but actual shifting has not yet been demonstrated. Using [<sup>68</sup>Ga]Pentixafor-PET/MRI for <i>in vivo</i>...
<div>Abstract<p>Personalized medicine aims to match the right drug with patient by using specific features of individual patient's tumor. However, current strategies personalized therapy matching provide treatment opportunities for less than 10% patients cancer. A promising method may be profiling biopsy specimens single-cell resolution directly quantify effects. We prospectively tested an image-based functional precision (scFPM) approach guide treatments in 143 advanced...
<div>Abstract<p>Bruton tyrosine kinase inhibitor ibrutinib is effective in treating chronic lymphocytic leukemia (CLL). However, after treatment initiation, patients frequently experience an increase of CLL blood cell count. This phenomenon clinical practice thought to reflect a “compartment shift” cells from lymph nodes the peripheral blood, but actual shifting has not yet been demonstrated. Using [<sup>68</sup>Ga]Pentixafor-PET/MRI for <i>in vivo</i>...
<p>Supplementary Data containing the statistical analysis plan, Supplemental Figures 1-6 and Tables 1 2</p>
<p>Supplementary Data containing the statistical analysis plan, Supplemental Figures 1-6 and Tables 1 2</p>